Welcome to our dedicated page for Opko Health SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company. These documents include current reports on Form 8-K and other periodic reports in which OPKO discloses financial results, significant transactions and operational updates.
Form 8-K current reports capture material events such as the announcement of quarterly operating and financial highlights and the completion of notable transactions. For example, OPKO has filed an 8-K describing a press release with results of operations and financial condition for a quarter, and another 8-K detailing the completion of the sale of certain BioReference Health oncology and related clinical assets to Labcorp under an asset purchase agreement.
Through its SEC filings, OPKO outlines segment performance in its pharmaceutical and diagnostics activities, provides information on capital structure changes such as convertible note exchanges, and describes collaboration agreements and asset sales. Exhibits to these filings often include press releases that summarize business highlights and explain how to access related conference calls and webcasts.
On Stock Titan, OPKO’s SEC filings are updated as they become available from the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as quarterly results, transaction terms, and other events described in Forms 8-K and other filings. Users can quickly identify filings that discuss diagnostics operations at BioReference, collaborations involving ModeX Therapeutics, and other developments that OPKO reports to regulators and investors.
OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D., reported multiple open-market purchases of OPKO common stock. On 11/21/2025, he bought blocks of 102,371, 3,894, 89,375, 191,490 and 192,870 shares at prices ranging from $1.30 to $1.335 per share. After these transactions, one line shows 216,706,448 shares of common stock beneficially owned indirectly as indicated in footnote (1). Separate lines show 3,568,951 shares held directly and 30,127,177 shares held indirectly as described in footnote (2).
Footnote (1) explains that certain shares are held by Frost Gamma Investments Trust and related entities, and footnote (2) explains holdings in Frost Nevada Investments Trust and related entities. In both cases, the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
OPKO Health (OPK) insider trading report: Phillip Frost, M.D., who serves as CEO, Chairman, director and a 10% owner of OPKO Health, reported a series of open-market purchases of the company’s common stock. On 11/20/2025, he bought a total of 580,000 common shares in multiple trades at prices ranging from $1.32 to $1.35 per share, all reported as indirect ownership through Frost Gamma Investments Trust. After these transactions, one reported indirect position shows 216,126,448 shares beneficially owned. The filing also lists 3,568,951 shares held directly and an additional 30,127,177 shares held indirectly through Frost Nevada Investments Trust. The report states that beneficial ownership is disclaimed except to the extent of any pecuniary interest.
OPKO Health (OPK) insider Phillip Frost, M.D., who serves as CEO, Chairman and a 10% owner, reported multiple open market purchases of the company’s common stock. On 11/19/2025, he bought a total of 580,000 shares in several transactions at prices ranging from $1.28 to $1.32 per share. Following these transactions, he was reported as indirectly beneficially owning 215,546,448 shares through Frost Gamma Investments Trust, with additional holdings of 3,568,951 shares directly and 30,127,177 shares indirectly through Frost Nevada entities, while expressly disclaiming beneficial ownership beyond his pecuniary interest.
OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D. reported multiple purchases of OPKO common stock on 11/18/2025. The transactions, coded as open-market or private purchases, ranged from $1.245 to $1.29 per share across several small trades.
Following these transactions, Frost is shown as beneficially owning 214,966,448 OPKO shares indirectly, as noted in a footnote describing Frost Gamma Investments Trust and related entities. Additional holdings of 3,568,951 shares are listed as directly owned, and 30,127,177 shares as indirectly owned through Frost Nevada Investments Trust, with both positions also accompanied by detailed ownership-disclaimer language. Frost is identified as a director, 10% owner, CEO and Chairman of OPKO Health.
OPKO Health (OPK): Phillip Frost, M.D., the company’s CEO, Chairman, Director and a 10% owner, reported an open‑market purchase of 150,000 shares of common stock on 10/31/2025 at a weighted average price of $1.4229. The price reflects multiple trades between $1.415 and $1.4299.
Following the transaction, reported beneficial ownership includes 3,568,951 shares direct, 214,386,448 shares indirect held by Frost Gamma Investments Trust, and 30,127,177 shares indirect held by Frost Nevada Investments Trust. The filing notes trust structures and standard beneficial ownership disclaimers.
OPKO Health filed its Q3 2025 10‑Q, reporting a profitable quarter driven by an asset sale. Total revenue was $151.7 million versus $173.6 million a year ago, with services at $95.2 million, products at $37.7 million, and transfer of intellectual property and other at $18.7 million. Operating income rose to $48.1 million from $14.2 million, aided by a $101.6 million gain on the sale of BioReference’s oncology diagnostics business to Labcorp.
Net income was $21.6 million (basic EPS $0.03), compared to $24.9 million last year. For the nine months, revenue was $458.4 million and net loss was $194.4 million, reflecting higher interest expense and the absence of prior‑year gains. Cash, cash equivalents and current restricted cash were $415.2 million, with total assets of $2.00 billion and total liabilities of $690.0 million.
The Labcorp oncology transaction delivered $192.5 million in consideration, including $173.3 million in cash and $19.2 million in escrow, plus up to $32.5 million in contingent consideration. OPKO continued its repurchase program, buying 24.3 million shares year‑to‑date for approximately $33.5 million, bringing total program spend to about $73.8 million. As of October 17, 2025, 767,701,280 common shares were outstanding. The company disclosed a foreign tax assessment of approximately $246 million; it has recorded a $9.9 million accrual related to uncertain tax positions.
OPKO Health (OPK) furnished an 8-K stating it issued a press release with operating and financial highlights for the quarter ended September 30, 2025. The release also explains how to access the company’s conference call covering third-quarter results and provides financial guidance. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and a copy of the press release is attached as Exhibit 99.1.
OPKO Health completed the sale of certain BioReference oncology and oncology-related laboratory testing business assets to Laboratory Corporation of America Holdings for up to
Phillip Frost M.D. and related entities reported multiple dispositions of OPKO HEALTH, INC. (OPK) common stock on 08/18/2025. The Form 4 shows a reported sale (transaction code G) of 440,000 shares for $0 and additional dispositions of 3,568,951 shares. Following the reported transactions, the filing lists 214,236,448 shares and 30,127,177 shares held indirectly by affiliated trusts and entities, with ownership described in footnotes clarifying trustee/beneficiary relationships. The filing is signed by Phillip Frost, M.D., individually and as trustee, indicating the report covers both his individual and related trust holdings.